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Many immunologic aspects of atopic dermatitis have been 
studied, but basic pathobiologic mechanisms of this disease 
remain unknown. In this study, we measured the production 
of interleukin-6 (IL-6) by peripheral blood T cells and mon-
ocytes from patients with atopic dermatitis in comparison to 
normal control subjects and patients with chronic psoriasis. 
We found that peripheral blood T cells isolated from patients 
with atopic dermatitis produced significantly higher levels of 
IL-6 (36.1 ± 5.1 units/ml, n = 22) than T cells derived from 
either normal subjects (12.6 ± 1.9 units/ml, n = 22) or pa-
tients with chronic psoriasis (26.7 ± 4.1 units/ml, n = 7). T-
cell activation was also measured in the patients with atopic 
dennatitis by soluble serum IL-2 receptor levels and were found 
A topic dermatitis (AD) is a multifactorial disorder asso-ciated with hereditary, environmental, and immuno-logic abnormalities, including overproduction of serum immunoglobulin E [1], impaired delayed-type hypersensitivity (DTH) responses [2], low prolifera-
tive responsiveness of cultured AD lymphocytes to antigen and 
mitogen stimulation in vitro [3,4], and altered natural killer cell 
activity [5]. 
Recently, it was reported that peripheral blood mononuclear cells 
(PBMC) isolated from patients with AD had defects in the secretion 
of certain cytokines, including decreased monocyte interleukin 1 
(IL-1) secretion [6], defective T-cell interferon-gamma (IFN-Y) pro-
duction [7], and decreased monocyte tumor necrosis factor-a 
(TNF-a) secretion [8] . Other studies indicated that T cells and 
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to be significantly higher (623.7 ± 8.1 wuts/ml, n = 8) than 
nonnal subjects (357.2 ± 26.0 wuts/ml, n = 8). In contrast to 
the increased production of IL-6 by T cells in atopic dennatitis, 
there was no significant difference in the IL-6 production by 
peripheral blood monocytes derived from patients with atopic 
dennatitis compared to normal subjects. Thus, peripheral blood 
T cells derived fromtatients with AD spontaneously produce 
increased amounts 0 IL-6 compared to T cells from nonnal 
subjects, which may reflect the increased activation state of T 
cel!s in atopic dermatitis. These data support the concept that 
actIvated T cells or subsets ofT cells may be important effector 
cells in mediating inflammatory activity in atopic disease. ] 
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T-cell clones from patients with AD secrete increased IL-4 com-
pared to normal subjects [9,10] . The latter report also suggests that 
fewer IFN-y-producing T cells in AD might relate both to the 
inadequate control of B-cell immunoglobulin E production and 
reduced DTH characteristic of AD. These findings are consistent 
with Mosmalm's hypothesis that subsets ofTh cells may be impor-
tant mediators of certain allergic diseases [11] . 
Another measurement ofT-cell activation is increased T-cell pro-
duction of cytokines such as IL-6 and increased serum soluble IL-2 
receptor (IL-2R) levels. IL-6 is a cytokine with a wide variety of 
effects on cells mediating inflammatory and immune responses. 
IL-6 induces acute phase proteins [12], stimulates B-cell differentia-
tion [13,14], promotes the growth of hybrid om as [15] and myeloma 
cells [16] , and enhances T-cell proliferation [17,18]. Irl vitro studies 
have revealed that IL-6 is produced by many cells including fibro-
blasts [19] , endothelial cells [20] , epithelial cells/keratinocytes [21] , 
and various lymphoid cells [22-26]. In clinical studies, IL-6 was 
also thought to be a mediator of the immunocompetent cell interac-
tions in many pathologic processes. Elevated IL-6 levels have been 
found in serum and culture supernatants ofPBMC in many inflam-
matory conditions such as rheumatoid arthritis [27], multiple mye-
loma [1 6], systemic lupus erythematosus [28] , and chronic psoriasis 
[29,30]. Dysregulation of IL-6 production may play an important 
role in mediating these diseases. However, the precise effects ofIL-6 
on lymphoid cells and other cytokine-secreting cells within the 
immunologic network of these diseases is unclear. Little is currently 
known regardi ng the contribution of T -cell- derived IL-6 in me-
diating inflammatory skin diseases. Previous studies have reported 
that activated T cells may contribute to the pathogenesis of AD 
[31 ,32]. Because of its broad inflammatory properties, we have ex-
amined the production of IL-6 by peripheral blood T cells isolated 
from patients with AD in comparison to T cells derived from nor-
mal healthy subjects or patients with chronic psoriasis. In addition, 
as another measurement of T-cell activation we have measured 
serum levels of soluble IL-2R from patients with AD compared to 
normal individuals. 
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Our results demonstrate that T cells, but not monocytes, isolated 
from patients with AD produce significantly higher levels of IL-6 
compared to normal subjects, perhaps reflecting an increased T-
cell-activation state in AD. Consistent with these results were the 
increased serum levels of IL-2R and increased expression of CD3/ 
CD25 on T cells isolated from PBMC detected in patients with AD. 
Increased T-cell IL-6 production may be indicative of increased type 
2 helper T-cell (Th2) functional activity in AD. 
MATERIALS AND METHODS 
Subjects Patients with AD were chosen accordi\1g to well-de-
fined criteria [33]. All were adu lts with chronic, mild to severe 
dermatitis, receiving no oral medications. Normal healthy subjects 
and patients with chronic psoriasis participating in this study had no 
personal or family history of asthma, allergic rhinitis, or eczema. 
Extent and severity of dermatitis in the AD patients were graded on 
five-point scales as previously described [2] . 
Cytokines and Antibodies Human recombinant IL-la (specific 
activity, 1 X 108 units/mg), IL-2 (specific activity, 2.5 X 106 units/ 
mg), granulocyte/macrophage colony-stimulating factor (specific 
activity,S X 107 proliferation units/mg), and IL-6 (specific activ-
ity,l X 107 units/mg) were purchased from Genzyme Corp. (Bos-
ton, MA). Human recombinant IL-4 (specific activity, 1 X 106 
units/mg) was a generous gift from Dr. Y.P. Yueng (Amgen, 
Thousand Oaks, CA). Human recombinant IFN-y (specific activity, 
1.9 X 107 units/mg) was kindly provided by Genentech, Inc. 
(South San Francisco, CA). The anti-CD3 monoclonal antibody 
(MoAb) Leu4, the anti-CDllc MoAb, LeuM5, and anti-CD14 
MoAb, LeuM3 were purchased from Beckton-Dickinson (Moun-
tain View, CA). Factor XIIIa MoAb was purchased from Calbio-
chern (La Jolla, CA). 
Preparation of the Supernatants PBMC were isolated from 
heparinized venous blood by Ficoll-Hypaque (Sigma, St. Louis, 
MO) centrifugation at 400 X g for 30 min. Cells were washed three 
times with saline, then suspended at 2 X 106 cells/ml in RPMI 1640 
(Gibco, Grand Island, NY) suppleme.nted with 10% heat-inacti-
vated fetal calf serum (FCS, Gibco), 1 % L-glutamine (Gibco), 1 % 
penicillin/streptomycin (Gibco) (complete RPMI) and incubated in 
24-well culture plates (Corning, New York, NY) at 37°C in humi-
dified atmosphere of 5% CO2 in air. For T-cell purification, PBMC 
were incubated at 2 X 106 cells/ml in complete RPMI for 2 h on 
plastic Petri dishes (Nunc, Roskilde, Denmark) to remove adherent 
cells. Non-adherent cells were collected and applied to a Human T 
Cell Recovery Column Kit (Biotex Lab, Edmonton, Canada). T-
cell supernatants were obtained by culturing 2 X 106 T cells/ml in 
complete RPMI at 37"C in humidified atmosphere of 5% CO2 in 
air using 24-well culture plates for indicated periods. In some ex-
periments, T-cell supernatants were obtained by culturing 2 X 106 
cells/ml of T cells in RPMI supplemented with heat-inactivated 
human AB serum (Sigma), 1 % L-glutamine, and 1 % penicillin/ 
streptomycin for 24 h at 37°C in humidified atmosphere of 5% 
CO2 in air. Monocyte supernatants were obtained by continuous 
culture of adherent cells (5 - 7 X 105 cells/ml) after removing the 
non-adherent cells in new complete RPMI at 37"C in humidified 
atmosphere of 5% in air for indicated periods. Supernatants were 
stored at -70°C until they were assayed for IL-6 bioactivity. All 
culture media used in these studies were screened for contaminating 
endotoxin by the E-Toxate Limulus amoebocyte bioassay (Sigma 
Chemical Company, St. Louis, MO). In blocking experiments, su-
pernatants were pre-incubated with 0.5 -10 mg/ml of mouse anti-
human IL-6 monoclonal antibody (Genzyme) for 1 h at 37 °C, 5% 
CO2 in air prior to use. 
Cell Characterization The PBMC contained 20 to 40% mono-
cytes, 60 to 70% lymphocytes, and 1 to 2% polymorphonuclear 
cells. T-cell fractions contained 97 to 99% of CD3+ cells and less 
than 1 % non-specific esterase+ monocytes. The monocyte fraction 
contained more than 98% non-specific esterase+, 95% CDl1c+, and 
more than 96% CD14+ and Factor XIIIa+l cells, when determined 
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by staining with MoAbs as described above or a-naphtylacetate 
esterase (Sigma). 
IL-6 Bioassay IL-6 bioactivity was measured by its proliferative 
action on the murine IL-6-dependent plasmacytoma B9 cell line 
[18]. The effects of several cytokines other than IL-6 on prolifera-
tive action of B9 cells were tested. No proliferation of the B9 cells 
used in these studies was observed when cultured with human IL-
Ia, IL-4 (50 -100 U/ml), IL-2 (5-100 U/ml), IFN-y (500-1000 
U /ml), or granulocyte/macrophage colony-stimulating factor 
(500 - 1000 ng/ml). The specificity of the B9 bioassay for IL-6 in 
the cell culture supernatants was further confirmed by anti-IL-6 
antibody-neutralization studies . Cells were maintained in RPM I 
supplemented with 5% FCS, 5 X 10- 5 M 2-mercaptoethanol (J .T . 
Baker, Phillipsburg, NJ), 1 % of penicillin/streptomycin, and 50 
units/ml of human rIL-6. For the assay, B9 cells were harvested by 
centrifugation and washed three times in Hanks' balanced salt solu-
tion. 5 X 103 cells were seeded in 96-well flat-bottomed microtiter 
plate (Falcon, Lincoln Park, NJ), containing 100 ml of a serial two-
fold dilution in media of the supernatants or sera to be tested. Serum 
samples from a group of AD, psoriatic, and normal subjects were 
heat-inactivated to 56 ° C for 30 min just prior to measuring the IL-6 
bioactivity. B9 cells were cultured for 48 h in 37°C, the last 6 h in 
the presence of 1 mCi/well of [3H]-thymidine (New England Nu-
clear, Boston MA). Incorporation of [3H]-thymidine was deter-
mined by liquid scintillation counter and expressed as mean cpm or 
units/ml of triplicate cultures determined by comparing the samples 
to a standard bioactivity curve using rIL-6 [34]. 
Determination of Soluble IL-2R in Serum To assay soluble 
IL-2R in the serum from AD and normal subjects, an enzyme-
linked immunosorbent assay (ELISA) with non-competing murine 
MoAb against IL-2R was used according to the manufacturer's pro-
tocol (T Cell Sciences, Inc., Cambridge, MA). Briefly, 96-well flat-
bottomed microtiter plates were coated with a MoAb against IL-2R 
(2R1.2). After blocking the non-specific binding, plates were 
washed three times with phosphate-buffered saline, and freshly 
thawed samples were added in duplicate and incubated for 2 h at 
37°C. Samples were then discarded, the plates were washed, and an 
antibody to the IL-2R conjugated with horseradish peroxidase was 
added to each well. After another 2 h incubation at 37°C, plates 
were washed and incubated with O-phenylenediamine-buffered 
solution containing hydrogen peroxidase. After 30 min at room 
temperature in the dark, color was developed by the addition of 2N 
sulfuric acid and the plates were read at 490 nm with microplate 
autoreader (Bio-Tek Instruments, Inc., Winooski, VT). Units of 
soluble IL-2R were calculated from a standard curve using soluble 
human IL-2R. 
Statistical Analysis Most data were expressed as mean ± 
standard error of the mean (SEM). Significance of differences be-
tween means were calculated using the Student t test. Differences 
between values were considered statistically significant at p < 0.05. 
Correlation was performed by linear regression and the strength of 
the linear relationship was estimated with Pearson product moment 
coefficient of correlation (r). 
RESULTS 
IL-6 Production by T Cells Derived from Patients with 
AD Freshly isolated Tcells (2 X 106 cells/ml) from AD, psoriasis, 
and normal subjects were cultured at 37"C for 24 h in complete 
RPMI and IL-6 bioactivity in the culture supernatants was measured 
in the B9 proliferation assay. Unstimulated T-cell culture superna-
tants from 22 patients with AD contained 36.1 ± 5.1 units/ml of 
IL-6 compared with 12.6 ± 1.9 units/ml of IL-6 in supernatants 
from T cells isolated from 22 normal subjects. For comparison we 
measured IL-6 activity in T-cell supernatants from patients with 
psoriasis and detected 26.7 ± 4.1 units/ml of IL-6 (Fig 1). Our 
studies indicated that freshly isolated T cells from patients with AD 
constitutively released significantly higher levels of IL-6 compared 
to equal numbers ofT cells from normal subjects (p < 0.005) and T 
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Figure 1. IL-6 production (mean ± SEM) by T cells from normal control 
subjects (NL, n = 22), patients with atopic dermatitis (AD, n = 22), and 
chronic psoriasis (PS, n = 7) was determined in the B9 proliferation assay. 
T-cell supernatants were obtained by culturing purified T cells (2 X 106 
cells/mI) in complete RPMI for 24 h at 37°C, 5% CO2 in air. IL-6 bioacti-
vity of these supernatants (1: 4 dilution) was measured by the B9 prolifer-
ation assay and expressed as units/ml of triplicate cultures determined by 
comparing the samples to a standard bioactivity curve using rIL-6. NS, 
not significant. 
cells derived from patients with psoriasis (p < 0.05). T cells from 
psoriatic patients also secreted higher levels of IL-6 compared to 
normal subjects but not to the significant levels of the AD subjects. 
Peripheral blood T cells from patients with allergic contact derma-
titis also secreted similar levels of IL-6 as the T cells derived from 
normal and psoriatic patients (data not shown). To confirm that the 
B9 proliferation activity in the cell supernatants was due to IL-6, we 
pre-incubated supernatants with anti-human IL-6 antibody for 1 h 
at 37°C. As shown in Fig 2, pre-incubation of the cell supernatants 
with anti - IL-6 antibody blocked the proliferative action of the 
supernatants on the B9 cells. In contrast, an anti - IL-4 antibody had 
no effect on this activity, thus indicating that the supernatant B9 
proliferative activity was due to IL-6. 
To rule out the possibility that the differential effect of AD su-
pernatants was due to factors in FeS, we carried out controls using 
serum-free medium or AB serum. We found that AD T cells again 
produced increased levels of IL-6 compared to normal T cells in 
medium supplemented with 5% human AB serum instead of 10% 
FeS. Medium supplemented with either Fes or AB serum did not 
induce B9 proliferation above baseline cpm (data not shown). It is 
possible that the differences in IL-6 detected in the AD and normal 
T-cell supernatants may be due to differences in the secretion of an 
IL-6 inhibitor; however, normal T-cell supernatants caused no in-
hibitory effect on recombinant IL-6 activity in the B9 bioassay. 
Therefore, T cells derived from patients with AD produce signifi-
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Figure 2. Effects of anti-IL-6 antibody on B9 proliferative response to 
AD (solid bars), or normal T-cell supernatants (mean ± SEM, n = 4). Su-
pernatants (1: 4 dilution) were added to the B9 cells alone or pre-incu-
bated with the anti-IL-6 antibody (5/lg/ml) or IL-4 antibody (5/lg/ml) for 
1 h and then bioactivity was measured by 3H-thymidine incorporation 
and quantitated by liquid scintillation spectroscopy. 
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Figure 3. IL-6 production by monocytes from patients with atopic derma-
titis (AD, n = 7) and normal (NL, n = 7) subjects. Monocyte supernatants 
were obtained by culturing purified monocytes (5 -7 X lOs cells/mI) in 
complete RPMI at 37°C, 5% CO2 in air for 24 h. IL-6 bioactivity of these 
supernatants (1 : 4 dilution) was measured by the B9 proliferation assay 
and expressed as units/ml of triplicate cultures (mean ± SEM). NS, not 
significant. 
candy higher IL-6 than those of normal subjects or patients with 
other non-atopic inflammatory skin diseases. 
IL-6 Production by Monocytes Derived from Patients with 
AD Because monocytes are a major source of IL-6 [23,24], we 
compared IL-6 producti~n by monocytes derived from AD patients 
coml'a.red to normal subjects. The IL-6 activity in 24-h monocyte-
condltloned supernatants from AD and normal subjects were mea-
sured in the B9 proliferation assay. As shown in Fig 3, atopic mono-
cytes (5-7 X 105 cells/ml, n = 7) released 33.6 ± 9.3 units/ml of 
IL-6 compared with 39.2 ± 9.2 units/ml of IL-6 from normal 
d?nors. T~us, in contra~t to T cells, . there was not a significant 
difference 111 the production of IL-6 bIOactivity by monocytes iso-
lated from atopic and normal subjects. However, these results also 
indicat.e that monocytes derived from AD and normal subjects pro-
duce higher basal levels ofIL-6 than the T cells tested in Fig 1. The 
monocytes (5 to 7 X 105 cells/ml) produced several times more 
IL-? ~n. a per cell basis ~ompar~d to the T cells (2 X 106 cells/ml) . 
TillS IS 111 agreement With prevIOus studies [23]. 
Kinetics of IL-6 Production by Freshly Isolated T Cells and 
~onocyt.es From AD and Normal Subjects We next exam-
1I1ed the time course of IL-6 production by freshly isolated T cells 
and ~ono.cytes from atopic .de~matitis and normal subjects. As indi-
cate~ 111 Fig 4, there was a slgmficant amount of IL-6 bioactivity in 
atopl.c T-cell supernatants as early as 3 h after culturing cells. This 
actiVity peaked at 24 h and declined thereafter. In contrast, IL-6 
bioactivity in normal T-cell supernatants was also detectable at 3 h 
but did no.t p~ak unt~l 48 h after culturing cells. Again the levels of 
IL-6 ~CtlVlty 111 atopic T-cell supernatants was significantly higher 
than 111 normal T-cell supernatants at all time points measured 
(Fig 4a). 
The kinetics of monocyte IL-6 production were also measured. 
Purified monocytes (5-7 X 105 cells/ml) from both atopic and 
normal donors also secreted detectable levels ofIL-6 after culturing 
cells for 3 h and this activity peaked after 24 h in tissue culture and 
then declined (Fig 4b). In contrast to the T-cell studies, there were 
no significant differences of IL-6 production between atopic and 
normal monocytes at any time point, consistent with the results in 
Fig 3. 
Thus, our results indicate that there are clear differences in both 
t?e ~rodu~tion an.d kinetics of freshly isolated T-cell IL-6 produc-
tion 111 patients With AD compared to normal subjects. This differ-
ence was not detected in the IL-6 production by monocytes from 
these same donors. 
1L-6 Bioactivity in Sera from Atopic Patients and Normal 
Subjects To determine if the increased IL-6 production by T cells 
isolated from patients with AD was reflected in increased serum 
levels of IL-6 in these same patients, we examined IL-6 bioactivity 
in serum from both atopic and normal subjects in comparison to 
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Figure 4. Kinetics of IL-6 production by T cells (A) and monocytes (B) 
from patients with AD (e) and normal (0) subjects. Purified T cells (2 X 
106 cells/ml) and monocytes (5 -7 X 105 cells/ml) were cultured in com-
plete RPMI at 37°C, 5% CO2 in air for the indicated periods. The data 
represent mean units/ml ± SEM of IL-6 bioactivity in three to seven 
different donors. "p < 0.05; ""not significant compared to normal sub-
jects. 
patients with chronic psonasls. Normal human serum contains 
poorly defined IL-6 inhibitory factors when measured in the B9 
bioassay (personal communication, Dr. Thomas Luger, Munster, 
Germany, 1991); therefore, we measured serum IL-6 bioactivity 
after first heating sera at 56 0 C for 30 min. Only low levels of IL-6 
bioactivity were detected in atopic and normal sera that was not heat 
treated (data not shown). After heat illactivation, IL-6 bioactivity 
was evident in sera from both atopic and normal subjects. However, 
as indicated in Fig 5, there was not a significant difference in the 
serum IL-6 activity in AD subjects compared to normal subjects. 
The serum from patients with psoriasis had a small , slightly signifi-
cant increase in IL-6 activity compared to normal subjects (p < 
0.05). Thus, the increased production of IL-6 by atopic T cells in 
vitro was not reflected in increased levels of serum levels of IL-6 in 
these patients. 
Correlation Between IL-6 Production by T Cells and Soluble 
IL-2R in Serum from Patients with AD and Normal Sub-
jects It has been reported that many patients with AD have an 
increased level of soluble IL-2R in serum, reflecting the activated 
E 
e 
Base Line AD (n=7) NL (n=7) PS (n=4) 
Figure 5. IL-6 bioactivity (mean ± SEM) in serum from patients with AD 
(n = 7), chronic pSOriasis (PS) (n = 4), and normal subjects (n = 7). Sera 
were heat-inactivated to 56°C for 30 min prior to use and diluted to 1 : 4 
with 89 cell medium. The cpm of all unheated sera were less than base line 
cpm of 89 cells. The value for psoriasis was significantly higher than for 
normal serum (p < 0.05). Error bar, SEM. 
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Table I . Correlation Between IL-6 Production by T Cells and 
Clinical Severity of Patients with AD 
Clinical Severity 
Mild 
Severe 
IL-6 Bioactivity (units/ml)' 
39.1 ± 5 .9 (n = 7) 
49.0 ± 9 .7 (n = 7)b 
• IL-6 bioactivity was detennined by the proliferative action of 89 cells. Data were 
exrressed as mean ± SEM of unitslm! of IL-6. 
No significant difference of IL-6 bioactivity compared to the patients with mild 
AD. 
state of the T cells in this disease [31,32]. In this study, we measured 
the serum IL-2R levels of the AD and normal subjects. We found 
that the mean soluble IL-2R level in serum from these AD patients 
was significantly higher (623.7 ± 83.1 units/ml, n = 8) than that 
of the serum IL-2R levels in normal subjects (357 .2 ± 26.0 units/ 
ml, n = 8). These results are consistent with an activated T-cell state 
in AD. The increased serum IL-2R levels in the AD patients was 
positively correlated with the increased spontaneous IL-6 produc-
tion by T cells in these patients, as demonstrated in Fig 6 (p < 0.05). 
We also examined the percentage of CD25+ cells as phenotypical 
analysis of activated T cells in patients with AD using flow cytome-
try. In the same patients (n = 8), we found a positive correlation 
between the increased production of T-cell IL-6 production (r = 
0.81, P < 0.05) and the increased CD25+ cells in PBMe. The pa-
tients with AD compared to the normal subjects as determined by 
fluorescence-activated cell sorter analysis (16.6 ± 3.1% for AD 
[n = 8] and lOA ± 2.6% for normals [n = 5], P < 0.05). 
Correlation Between T-Cell IL-6 Production and Clinical 
Severity in Patients With AD We questioned whether in-
creased AD T-cell IL-6 production related to disease severity in the 
subjects tested. IL-6 production levels by AD T cells was compared 
with the clinical severity of the AD in the study population. Al-
though IL-6 bioactivity in T-cell supernatants from patients with 
severe AD was higher than in patients with mild AD, the differ-
ences were not statistically significant among the 14 patients who 
could be clearly designated as having mild or severe AD (Table I). 
DISCUSSION 
This study has provided new and unexpected information relating 
T-cell IL-6 production and AD. We have demonstrated that freshly 
isolated unstimulated T cells from peripheral blood of patients with 
AD consistently release higher levels of IL-6 compared to T cells 
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Figure 6. Correlation, by linear regression, between IL-6 production by 
T cells and soluble IL-2R levels in serum from patients with AD (n = 6, 
solid circles) and normal subjects (n = 4, ope/l circles). Serum IL-2R was 
determined by ELISA using murine MoAb against IL-2R. The data were 
expressed as units/ml of IL-2R determined by the comparison of samples 
to a standard curve using human soluble IL-2R. 
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from normal healthy subj ects or patients with other inflammatory 
skin disorders. It is of particular signili.cance that highly purili.ed 
« 2% monocytes) atopic T cells produce high levels of IL-6 with-
out the addition of specili.c exogenous antigens or mitogens. In 
previous studies, it has been reported that T cells produced IL-6 only 
after phytohemagglutinin and phorbol stimulation and required the 
presence of monocytes, whereas normal resting T cells secreted 
little IL-6 [23,35] . Hori et at also reported that normal peripheral 
blood T cells produce IL-6 in a macrophage-dependent manner, and 
IL-6 mRNA expression was observed in only mitogen-stimulated T 
cells but not in resting T cells [23]. In other studies, IL-6 mRNA was 
demonstrated in human T-cell leukemia virus-1- infected T cells 
but not in normal T cells [22,26]. In contrast to a previous publica-
tion, we consistently detected some IL-6 production by normal T 
cells, which was significantly increased in AD T cells. This was not 
due to FCS components because we observed similar proliferative 
activities when human AB serum was used in our tissue culture 
medium. Likewise, endotoxin contamination was ruled out as a 
source of IL-6 induction by routinely screening tissue culture media 
by the E-toxate assay. The IL-6 produced by unstimulated normal T 
cells may be due to non-specific activation by culture conditions. 
Thus, our results demonstrate an example of increased IL-6 produc-
tion by freshly isolated T cells from patients with AD, which may 
reflect an activated state of the T cells in this disease. 
Because of its multi-functional properties, IL-6 is believed to be 
an important mediator of host immune and inflammatory re-
sponses. Originally, IL-6 was found to be produced by fibroblasts 
in certain inflammatory conditions [19] and subsequent studies 
showed that IL-6 was produced by monocytes [24], endothelial 
cells, epithelial cells [20], and keratinocytes [21]. Monocytes are 
thought to be a major source ofIL-6 in peripheral blood cells. Our 
li.ndings support this, showing that monocytes produced two to 
three times more IL-6 on a per cell basis than T cells in AD and 
normal subjects. However, we found no evidence for increased IL-6 
production by monocytes in AD patients compared to normal sub-
jects. Since AD and normal monocytes produced equal amounts of 
IL-6, it is unlikely that the differences in T-cell IL-6 production can 
be explained simply by monocyte-derived IL-6 carried into the T-
cell cultures by membrane absorption of IL-6. Moreover, we mea-
sured the IL-6 bioactivity in T-cell supernatants by culturing T cells 
(2 X 106 cells/ml) purili.ed by loading PBMC to the T-cell column 
directly without adherence. AD T cells isolated in this manner also 
produced signili.cantly higher IL-6 bioactivity than normal T cells 
and showed levels of IL-6 bioactivity similar to those from T cells 
obtained after the 2-h adherence removal of monocytes (data not 
shown) . Therefore, although monocytes may exert permissive ef-
fects on T-cell IL-6 production, they do not appear to be responsible 
for abnormal amounts of IL-6 in our AD T-cell studies because they 
represented less than 2% ofT-cell preparations and equal amounts 
of monocyte IL-6 would be carried in both normal and AD T-cell 
preparations. 
Others have suggested that activated T cells contribute to the 
pathogenesis of AD [31,32,36]. In the present study in addition to 
the increased T-cell IL-6 production, T-cell activation is reflected 
by the increased soluble IL-2R levels in the serum of patients with 
AD. Thus, our results are consistent with previous studies proposing 
that activated T cells contribute to AD [31,36]. The elevated T-cell 
IL-6 production in patients with AD may be a unique sign ofT-cell 
activation in atopy or a predominance ofTh2 subsets or both. This 
cytokine is capable of mediating a number of immunologic and 
inflammatory responses. The effects of IL-6 on B cells include the 
stimulation of cell growth, differentiation, and regulation ofimmu-
noglobulin isotype class [13,14]. IL-6 is also a mitogen for hepatic 
acute-phase protein synthesis [12], an endogenous pyrogen, and a 
r
otent T-cell activating factor that induces T-cell proliferation 
17,18]. 
We found that peripheral blood T cells from patients with aller-
gic contact dermatitis (ACD) produced levels ofIL-6 comparable to 
normal subjects and less than AD patients. This may reflect the local 
nature of ACD compared to the systemic manifestations of AD. The 
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consequence of this difference could be much higher numbers of 
IL-6-producing activated T cells in AD blood compared to ACD. 
Increased production of IL-6 by atopic T cells or subsets may con-
tribute to the local and systemic immunologic irregularities ob-
served in AD. There are many studies reporting elevated IL-6 pro-
duction by peripheral blood lymphoid cells in various systemic 
inflammatory diseases, such as rheumatoid arthritis [27] and sys-
temic lupus erythematosus [28] . Adelman et at reported that the 
serum from patients with common variable immunodeli.ciency dem-
onstrated elevated levels ofIL-6 [34]. Likewise, increased IL-6 activ-
ity was reported in suction blister fluid and in keratinocytes from 
patients with chronic psoriasis [30]. Our results indicated that IL-6 
production by peripheral blood T cells isolated from patients with 
chronic psoriasis was increased above levels of normal subjects but 
less than AD T cells. 
Serum IL-6 levels from AD subjects were similar to those of 
normal subjects, whereas serum from patients with chronic psoriasis 
had a small increase in IL-6 bioactivity. This is consistent with 
li.ndings by other investigators [30], though we are aware of one 
study i~ whic.h serum IL-6 was elevated in a subset of AD patients 
correlating With extensive body surface area of involvement (Dr. J. 
Krutmann, personal communication, 1992). In our study, normal 
serum IL-6levels were detected in AD patients despite cultured AD 
T cells producing increased amounts of IL-6. It is difficult to accu-
~ately measure serum IL-6Ievels. Secreted IL-6 is rapidly inactivated 
In the serum by circulating inhibitors, proteases, and serum binding 
proteins. Recent reports indicate that IL-6 is rapidly metabolized 
within a few minutes by serum proteases and is selectively deposited 
in the skin [37,38]. This tropism of IL-6 for the skin further sup-
ports a possible role ofT-cell IL-6 in AD. Serum IL-6 may also bind 
to other proteins thus making it undetectable by available ELISA 
kits (personal communication, Dr. L. May, Rockefeller University, 
NYC, NY). Elevated IL-6 production by AD T cells may reflect the 
increased activation state of these T cells in AD and may contribute 
to the cutaneous inflammation in this disease by the IL-6 activation 
oflymphoid and non-lymphoid cells in the skin. The identili.cation 
of spec.ifi~ T -c~ll subsets in the s~in secreting IL-6 in AD may give 
added inSight In the pathogeneSIs of this disease. 
It is possible that the increased levels of IL-6 produced by AD T 
cells IS due to lower levels of IL-6 inhibitor secreted by T cells in 
these patients. Although this possibility cannot be absolutely ruled 
out by our s~udies, i~ is unlikely because the T -cell supernatants from 
normal subjects faded to have any inhibitory activity in the B9 
bIOassay when the cells were stimulated with recombinant IL-6. 
Although there was increased T-cell IL-6 production in severe 
AD compared to mild AD, we failed to demonstrate a statistical 
correlation in .the small group of patients in our study group. A 
larger population of AD patients will be needed to adequately ad-
dress this issue. 
. There have been several reports concerning the secretion of cyto-
klnes by T cells and monocytes in patients with AD. Rasanen et at 
reported that the production of IL-1 by monocytes was impaired in 
AD and that atopiC monocytes failed to induce T-cell activation [6]. 
Reinhold et at reported that a significant proportion of patients with 
AD had an impaired capacity to produce IFN-y in vitro, and this was 
correlated with increased serum immunoglobulin E and immuno-
globulin G4 levels and associated with an increased proportion of 
IL-4 producing T cells [8]. Increased T-cell-derived IL-4 may be 
responsible for increased immunoglobulin E production by B cells 
characteristic of AD. It has been reported that there are two types of 
T helper cell subsets in a murine model and more recently in 
humans, which differ in the pattern oflymphokine release [11,39]. 
Th 1 cells release predominantly IL-2 and IFN-y and Th2 cells re-
lease IL-4, IL-5, and IL-6, but not IFN-y. The increased IL-6 rro-
duction by atopic T cells may be the result of the activation 0 the 
Th2 subset. This may contribute to the dysregulation of immuno-
globulin E production by B cells in AD. 
In this study, we have demonstrated that T cells from patients 
with atopic dermatitis have the capacity to produce significant 
levels of IL-6 spontaneously, and at higher levels than T cells from 
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normal subjects. These findings suggest that elevated T cell IL-6 
production may contribute to the inflammation in AD. However, 
the precise role of these IL-6 secreting T cells in the pathogenesis of 
AD remains to be determined. 
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